Option chain shows key data for Charlottes Web Holdings's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Charlottes Web Holdings.

Charlottes Web Holdings (OTC:CWBHF) Stock, Option Chain

Charlottes Web Holdings

Charlottes Web Holdings Inc is engaged in the production and distribution of hemp-based cannabidiol (CBD) wellness products. Its product categories include ingestible products (tinctures, capsules, and gummies), topicals, and pet products. The company distributes its products through an e-commerce website, third-party e-commerce websites, select distributors, health practitioners, and a variety of brick-and-mortar specialty retailers.

ibrahim-rifath-OApHds2yEGQ-unsplash(7)

Cannabis

Earnings

News

CWBHF

CWEB

TLRY

TSX:CWEB

Charlotte&#39;s Web Holdings, Inc. (TSX: CWEB) (OTCQX: CWBHF) a producer of hemp-derived CBD and other botanical wellness products, reported on Thursday financial results for the third quarter ended Sept. 30, 2024. CEO of Charlotte&#39;s Web,&#34; Bill Morachnick, CEO of Charlotte&#39;s Web, said. &#34;We&#39;ve seen positive impacts from our e-commerce platform upgrades, recent product launches, and additional retailers, highlighted by our new partnership with Walmart that brings our CBD topicals to another 827 stores.&#34;

CBD Pioneer Charlotte&#39;s Web Narrows Loss In Q3, Focuses On Long-Term Growth

elsa-olofsson-NgoMswTX-aU-unsplash

Retail Sales

TSX:TLRY

Cannabis giant Tilray Brands, Inc. (NASDAQ: TLRY) (TSX: TLRY) announced on Monday the launch of new Charlotte&#39;s Web (TSX: CWEB) (OTCQX: CWBHF) CBD gummies in Canada. The new gummies hit shelves in select cannabis retailers across Ontario. The products will be available in select provinces and retailers this October and November. Utilizing Tilray Medical website, the products will be available online as well.

Two Cannabis Power Houses Team Up: Tilray Brings CBD Gummies From US Medical Marijuana Pioneer To Canada

Cannabisl Regulation (Shutterstock)

Government

Regulations

Politics

Sen. Ron Wyden (D-OR) made headlines a week ago after introducing the Cannabinoid Safety and Regulation Act (CSRA), a measure that seeks to set up a federal framework for regulating hemp-derived cannabinoids like CBD and Delta-8 THC.  On Wednesday, ONE HEMP hailed Congressional action toward the regulation of CBD as a dietary supplement, calling the move &#34;long overdue.&#34; The coalition of industry leaders was committed to advancing regulatory standards for hemp-derived cannabinoid (CBD) products for years.

Congressional Bill Is Game-Changer For CBD Regulation, It&#39;s &#39;Long Overdue,&#39; Says Hemp Coalition

CHARLOTTES WEB HLDGS INC by Charlotte's Web Holdings Inc.

Charlottes Web Holdings Inc

Trimble will provide fleet management and telematics solutions to vehicles across PFG's three business segments including Performance Foodservice Core-Mark and Vistar.&nbsp;
All PFG vehicles will be equipped with Trimble Instinct, Trimble's in-cab ecosystem that seamlessly connects drivers and back-office staff to boost safety, compliance and efficiency.
 &nbsp;

Contracts

PFGC

TRMB

Performance Food Group Selects Trimble As Its Premier Fleet Management Provider; Migrates 100% Of Its Fleet Management Business To Trimble Instinct, Doubling Trimble-Serviced Trucks To Over 8,000

Citigourp Global Markets 2% Protected Notes Linked To The Djia

PDD Holdings Q3 Adj EPADS $2.65 Misses $2.82 Estimate, Sales $14.16B Miss $14.47B Estimate

Artificial intelligence (AI) darling Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) <a href="https://www.benzinga.com/news/earnings/24/11/42099904/nvidia-beats-q3-revenue-eps-estimates-supply-constraints-ding-stock-huang-says-age-of-ai-is-in-full-steam">beat expectations yet again</a> with impressive third-quarter revenue and earnings reported after Wednesday's market close. 
What happened: The world's most valuable company <a href="https://www.benzinga.com/24/11/42099904/nvidia-q3-earnings-highlights">disclosed </a>third-quarter revenue of $35.1 billion and earnings per share of 81 cents, both beating analysts' estimates.&nbsp;
The Jensen Huang-led firm has had a blockbuster run on equity markets in the last few years, multiplying investors' money by orders of magnitude.&nbsp;
Indeed, Nvidia shares have exploded by 2,718% in the last five years, outperforming all well-known companies on Wall Street.
In comparison, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)—the world's most valued cryptocurrency exerting a similar influence on the digital assets market—grew 1,171% over the last five years.
See Also: <a href="https://www.benzinga.com/24/11/42079799/microstrategys-michael-saylor-to-advocate-for-bitcoin-investment-at-microsoft-board-meeting-offers-to-educate-rumble-ceo-with-the-strategy">Microstrategy&#8217;s Michael Saylor To Advocate For Bitcoin At Microsoft Board Meeting, Offers To Educate Rumble CEO As Well</a>
<h2 class="wp-block-heading">Which Is Offering Better Returns Relative To Risk?</h2>
Both Nvidia and Bitcoin are risk-laden investments, and traders must navigate their inherent volatility to profit.
To get a more accurate picture, analysts track the Sharpe Ratio, a measure of risk-adjusted returns. 
For Bitcoin, this ratio stood at -5 as of this writing, <a href="https://in.tradingview.com/chart/XlzxagWe/?symbol=BITSTAMP%3ABTCUSD">per </a>TradingView, implying that the expected return was lower than that of a risk-free investment, such as a Treasury yield.&nbsp;
On the other hand, Nvidia <a href="https://www.tradingview.com/chart/XlzxagWe/?symbol=NASDAQ%3ANVDA">showed </a>a Sharpe ratio of 0.69, indicating that investment in the stock was generating positive returns above the risk-free rate.
<h2 class="wp-block-heading">Are Their Valuations Inflated?</h2>
Another metric to compare the two hot financial assets was whether they were expensive or cheap relative to their fundamentals.
For stocks, this is typically measured by the price-to-earnings ratio, or simply the P/E ratio.&nbsp;
Nvidia's P/E ratio showed a reading of 73.478 per TradingView, suggesting that the stock was highly overpriced. It could also imply that investors expect the company to have stronger performance and higher earnings in the future.
The P/E counterpart for Bitcoin is the network value to transactions ratio or NVT ratio.
According to on-chain analytics firm <a href="https://cryptoquant.com/asset/btc/chart/network-indicator/nvt-ratio?window=DAY&amp;sma=0&amp;ema=0_30&amp;priceScale=log&amp;metricScale=log&amp;chartStyle=column">CryptoQuant</a>, the 30-day EMA of Bitcoin's NVT was at 28.28 at the time of writing, a decline from 36.32 recorded at the beginning of the month.
The decline implied that transaction volume was outperforming market growth or that valuation had dropped without any change in transaction activity.
Price Action: At the time of writing, Bitcoin was trading at $97,396.60, rising 4.97% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>. Shares of Nvidia were down 2.49% in after-hours trading.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/11/42079984/dogecoin-bitcoin-left-in-the-dust-by-ai-meme-coin-goat-as-nvidias-q3-earnings-draw-near">Dogecoin, Bitcoin Left In The Dust By AI Meme Coin GOAT As Nvidia&#8217;s Q3 Earnings Draw Near</a></li>
</ul>
Photos courtesy: Nvidia and Pixabay

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

Tech

$BTC

NVDA

Nvidia Vs. Bitcoin: Jensen Huang-Led Chip Giant's Stock Outperformed The Top Cryptocurrency Over 5 Years. Here's How They Compare On Other Metrics

Benchmark analyst Cody Acree maintains NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) with a Buy and raises the price target from $170 to $190.

Price Target

Analyst Ratings

Benchmark Maintains Buy on NVIDIA, Raises Price Target to $190

Roth MKM analyst Joe Reagor initiates coverage on Stardust Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDST#NASDAQ">SDST</a>) with a Buy rating and announces Price Target of $13.

Initiation

SDST

Roth MKM Initiates Coverage On Stardust Power with Buy Rating, Announces Price Target of $13

Morgan Stanley analyst James Faucette upgrades Evertec (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVTC#NYSE">EVTC</a>) from Underweight to Equal-Weight and raises the price target from $33 to $35.

Upgrades

EVTC

Morgan Stanley Upgrades Evertec to Equal-Weight, Raises Price Target to $35

Morgan Stanley analyst Brian Wilczynski initiates coverage on UMB Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UMBF#NASDAQ">UMBF</a>) with a Overweight rating and announces Price Target of $156.

UMBF

Morgan Stanley Initiates Coverage On UMB Financial with Overweight Rating, Announces Price Target of $156

Needham analyst Quinn Bolton maintains NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) with a Buy and raises the price target from $145 to $160.

Needham Maintains Buy on NVIDIA, Raises Price Target to $160

Morgan Stanley analyst Judah Frommer initiates coverage on 4D Molecular Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDMT#NASDAQ">FDMT</a>) with a Underweight rating and announces Price Target of $8.

FDMT

Morgan Stanley Initiates Coverage On 4D Molecular Therapeutics with Underweight Rating, Announces Price Target of $8

Morgan Stanley analyst Judah Frommer initiates coverage on Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Equal-Weight rating and announces Price Target of $31.

APLS

Morgan Stanley Initiates Coverage On Apellis Pharmaceuticals with Equal-Weight Rating, Announces Price Target of $31

Quantum-Si Provides Update On Innovation Roadmap & New Development Partnerships; Announces Next-Generation Platinum System, The Platinum Pro, Scheduled To Launch In H1 Of 2025

Guidance

SCVL

Shoe Carnival Lowers FY24 Net Sales Outlook: Sees Revenues Of $1.20B-$1.23B Vs $1.23B Estimate (Prior View:  $1.23B-$1.25B); Company Reiterates FY24 Adjusted EPS Outlook Of $2.60-$2.75 Vs. $2.63 Estimate

With more than a week of deals planned across the entire assortment, Target will offer some of its lowest prices of the season on thousands of items, including up to 50% off tech, apparel, video games, board games, small appliances, luggage, holiday trees and other must-have items for gifting and gathering.

Target Reveals Its Lineup Of Black Friday Deals Available Now Through Nov. 30 Online And In Its Stores

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintains Quantum-Si (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) with a Buy and raises the price target from $4 to $5.5.

HC Wainwright & Co. Maintains Buy on Quantum-Si, Raises Price Target to $5.5

This collaboration aims to accelerate the development of advanced ceramic-based microspheres, a groundbreaking advancement in radiotherapeutic applications.
The partnership will see SINTX leverage its expertise in ceramic manufacturing to support NED medical's pre-clinical testing needs and perform the necessary process validation and verification activities to transition the microsphere process from the R&amp;D scale to pilot production.

SINT

SINTX  Signs Joint Development Agreement With NED Medical To Develop Next Generation Radiotherapeutic Solutions That May Have Transformative Impact On Cancer Treatment

Shoe Carnival (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCVL#NASDAQ">SCVL</a>) reported quarterly earnings of $0.71 per share which beat the analyst consensus estimate of $0.67 by 5.97 percent. The company reported quarterly sales of $306.885 million which missed the analyst consensus estimate of $316.950 million by 3.18 percent. This is a 4.07 percent decrease over sales of $319.914 million the same period last year.

Earnings Beats

Earnings Misses

Shoe Carnival Q3 2024 Adj. EPS $0.71 Beats $0.67 Estimate, Sales $306.885M Miss $316.950M Estimate

GEHC

GE HealthCare Sets Medium-Term 2026-2028 Targets: Organic Revenue Growth Mid-Single Digit (4% - 6%), Adjusted EPS Growth High-Single Digit To Low-Double Digit

Keefe, Bruyette &amp; Woods analyst Damon Delmonte initiates coverage on Northeast Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBN#NASDAQ">NBN</a>) with a Market Perform rating and announces Price Target of $102.

Keefe, Bruyette & Woods Initiates Coverage On Northeast Bank with Market Perform Rating, Announces Price Target of $102

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Biomea Fusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) with a Buy and maintains $40 price target.

Reiteration

BMEA

HC Wainwright & Co. Reiterates Buy on Biomea Fusion, Maintains $40 Price Target

GE HealthCare Reiterates 2024 Outlook For Organic Revenue Growth Trending Toward Lower End Of 1% - 2% Range; Continues To See Adjusted EPS $4.25 - $4.35 (Est $4.29)

Charlotte's Web Holdings (TSE:CWEB) has released an update. Charlotte's Web Holdings, Inc. is set to announce its 2024 second quarter earnings befo...

Charlotte's Web Readies for Q2 Earnings Announcement

Here is the next potential market catalyst

Charlotte's Web Holdings GAAP EPS of -$0.07 misses by $0.02, revenue of $12.29M misses by $1.92M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Charlottes Web Holdings (OTCMKTS:<a href="https://investorplace.com/stock-quotes/cwbhf-stock-quote/">CWBHF</a>) just reported results for the second quarter of 2024.<ul><li>Charlottes Web Holdings reported earnings per share of -7 cents. This was below the analyst estimate for EPS of -5 cents.</li><li>The company reported revenue of $12.29 million.</li><li>This was 6.90% worse than the analyst estimate for revenue of $13.20 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/cwbhf-stock-earnings-charlottes-web-holdings-for-q2-of-2024/">CWBHF Stock Earnings: Charlottes Web Holdings Misses EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CWBHF Stock Earnings: Charlottes Web Holdings Misses EPS, Misses Revenue for Q2 2024

Charlotte's Web Holdings Inc. (CWBHF) Q2 2024 Earnings Call Transcript

Benchmark Co. analyst Mike Hickey maintained a Hold rating on Charlotte's Web Holdings (CWBHF – Research Report) today. The company's shares closed...

Benchmark Co. Reaffirms Their Hold Rating on Charlotte's Web Holdings (CWBHF)

American views on marijuana effects worsening: Gallup

Charlotte's Web Holdings (TSE:CWEB) has released an update. Charlotte's Web Holdings, a leader in CBD wellness products, opposes new California reg...

Charlotte's Web Challenges New California CBD Regulations

Charlotte's Web Holdings (TSE:CWEB) has released an update. Charlotte's Web Holdings celebrates a significant legislative step as Congress moves to...

Charlotte's Web Applauds New CBD Dietary Supplement Bill

Charlotte's Web Holdings GAAP EPS of -$0.04 in-line, revenue of $12.6M misses by $0.39M

AAWH

ACDC

AGEN

ALIZF

AMPX

AUTL

AXGN

AYRWF

BITF

BKSY

CARS

CBSTF

CCOI

CEIX

CION

CNBS

COLD

COMM

CRLBF

CRNC

CRON

CURLF

CYBR

DCBO

DNUT

DTEGY

EDRY

ELAN

EPAM

ETRGF

FLGC

FOLD

FOUR

FWONA

GDRX

GLASF

GTBIF

HITI

JUSHF

MAPS

MRMD

PCLOF

PLNH

SNDL

TCNNF

VRNOF

YCBD

YOLO

Screenshot 2024-08-30 at 5.32.57 PM

Biotech

AJNA BioSciences&#39; Strategy For Market Leadership In Botanical Drug Development With Magic Mushrooms And Cannabis

Small Cap

Press Releases

Charlotte's Web Debuts at Walmart with New CBD Topical Collection

Charlotte's Web 2024 Second Quarter Earnings Call and Webcast Notice

Charlotte's Web Reports 2024 Second Quarter Financial Results

AJNA BioSciences' Strategy For Market Leadership In Botanical Drug Development With Magic Mushrooms And Cannabis

Charlotte's Web Responds to New Regulatory Developments in California Affecting the Sale of Hemp CBD Products

ONE HEMP Hails Long Overdue Congressional Action Toward the Regulation of CBD as a Dietary Supplement

Comments

Charlottes Web Holdings

Charlottes Web Holdings (CWBHF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga